These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20606064)

  • 1. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole.
    Queenan AM; Shang W; Bush K; Flamm RK
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4092-7. PubMed ID: 20606064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M; Mills JC; Farrell DJ; Jones RN
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of MexXY overexpression on ceftobiprole susceptibility in Pseudomonas aeruginosa.
    Baum EZ; Crespo-Carbone SM; Morrow BJ; Davies TA; Foleno BD; He W; Queenan AM; Bush K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2785-90. PubMed ID: 19433554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins.
    Berrazeg M; Jeannot K; Ntsogo Enguéné VY; Broutin I; Loeffert S; Fournier D; Plésiat P
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6248-55. PubMed ID: 26248364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G; Ocampo-Sosa AA; Tubau F; Macia MD; Rodríguez C; Moya B; Zamorano L; Suárez C; Peña C; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxacillinase-mediated resistance to cefepime and susceptibility to ceftazidime in Pseudomonas aeruginosa.
    Aubert D; Poirel L; Chevalier J; Leotard S; Pages JM; Nordmann P
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1615-20. PubMed ID: 11353602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
    Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
    J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB; Rodríguez MC; Campo-Sosa AO; Rodríguez C; Martínez-Martínez L
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.
    Lahiri SD; Walkup GK; Whiteaker JD; Palmer T; McCormack K; Tanudra MA; Nash TJ; Thresher J; Johnstone MR; Hajec L; Livchak S; McLaughlin RE; Alm RA
    J Antimicrob Chemother; 2015; 70(6):1650-8. PubMed ID: 25645206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM
    Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B; Zamorano L; Juan C; Pérez JL; Ge Y; Oliver A
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.
    Rodríguez-Martínez JM; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2009 May; 53(5):1766-71. PubMed ID: 19258272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of Pseudomonas-Derived Cephalosporinase and Metallo-β-Lactamases in Carbapenem-Resistant Pseudomonas aeruginosa Isolates from Korea.
    Cho HH; Kwon GC; Kim S; Koo SH
    J Microbiol Biotechnol; 2015 Jul; 25(7):1154-62. PubMed ID: 25907063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
    Zamorano L; Reeve TM; Juan C; Moyá B; Cabot G; Vocadlo DJ; Mark BL; Oliver A
    Antimicrob Agents Chemother; 2011 May; 55(5):1990-6. PubMed ID: 21357303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM; Choi JY; Lee JY; Kang CI; Chung DR; Peck KR; Song JH; Ko KS
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of Fe uptake systems and AmpC β-lactamase in susceptibility to the siderophore monosulfactam BAL30072 in Pseudomonas aeruginosa.
    van Delden C; Page MG; Köhler T
    Antimicrob Agents Chemother; 2013 May; 57(5):2095-102. PubMed ID: 23422914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa.
    Watanabe N; Hiruma R; Katsu K
    J Antimicrob Chemother; 1992 Nov; 30(5):633-41. PubMed ID: 1493980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.
    Drusano GL; Bonomo RA; Bahniuk N; Bulitta JB; Vanscoy B; Defiglio H; Fikes S; Brown D; Drawz SM; Kulawy R; Louie A
    Antimicrob Agents Chemother; 2012 Jan; 56(1):231-42. PubMed ID: 22005996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.